We Claim:

1. A therapeutically effective combination for treatment of cancer in a subject, comprising a recombinant lectin protein derived from *Sclerotium rolfsii* lectin and one or more other therapeutic agent, wherein the combination is synergistic and wherein the concentration of recombinant lectin protein is in the range from 0.5 µg/mL to 100 µg/mL wherein the combination is a composition;

   wherein the concentration of one or more other therapeutic agent is in a range from 0.1 nM to 1000 µM;

   the recombinant lectin protein derived from *Sclerotium rolfsii* lectin is a protein having amino acid sequence of SEQ. ID NO:1, SEQ. ID NO: 2 or SEQ. ID NO: 3 and

   wherein the other therapeutic agent is an anticancer agent.

2. Use of a therapeutically effective combination comprising a recombinant lectin protein derived from *Sclerotium rolfsii* lectin and one or more other therapeutic agent for the manufacture of a medicament for the treatment of cancer in a subject, wherein the combination is synergistic and wherein the concentration of recombinant lectin protein is in the range from 0.5 µg/mL to 100 µg/mL wherein the combination is a composition;

   wherein the concentration of one or more other therapeutic agent is in a range from 0.1 nM to 1000 µM; the recombinant lectin protein derived from *Sclerotium rolfsii* lectin is a protein having amino acid sequence of SEQ. ID NO:1, SEQ. ID NO: 2 or SEQ. ID NO: 3 and wherein the other therapeutic agent is an anticancer agent.

3. The therapeutically effective combination, according to claim 1, wherein the anticancer agent is an antimetabolite, an alkylating antineoplastic agent, an anti-microtubule agent and/or a topoisomerase I inhibitor; the antimetabolite is selected from 5-Flurouracil (5-FU), Gemcitabine, Methotrexate, Pemetrexed or Capecitabine; the alkylating neoplastic agent is a platinum based anti-neoplastic agent selected from cisplatin or carboplatin; the anti-microtubule agent is selected from Paclitaxel, Docetaxel, Abraxane or Taxotere; the topoisomerase I inhibitor is selected from Irinotecan or Topotecan.

4. The therapeutically effective combination, according to claim 1, wherein the anticancer agent is cisplatin and wherein the cancer is oral, ovarian or bladder cancer.

5. The therapeutically effective combination, according to claim 1, wherein the anticancer agent is 5-FU and wherein the cancer is oral, pancreatic or colon cancer.

6. The therapeutically effective combination, according to claim 1, wherein the anticancer agent is Irinotecan and wherein the cancer is colon cancer.

7. The therapeutically effective combination, according to claim 1, wherein the anticancer agent is Paclitaxel and wherein the cancer is ovarian or breast cancer.

8. The therapeutically effective combination, according to claim 1, wherein the anticancer agent is Gemcitabine and wherein the cancer is bladder or pancreatic cancer.

9. The therapeutically effective combination, according to claim 1, wherein the anticancer agent is carboplatin and wherein the cancer is breast cancer.

10. The therapeutically effective combination according to any one of claims 1 or 4-10, wherein the concentration of the recombinant lectin protein derived from *Sclerotim rolfsii lectin* is in the range from 1 µg/mL to 90 µg/mL.

11. The therapeutically effective combination, according to claim 1, wherein the concentration of Cisplatin is in the range of 0.01 µM to 500 µM.

12. The therapeutically effective combination, according to claim 1, wherein the concentration of 5-Flurouracil (5-FU) is in the range of 0.01 µM to 250 µM.

13. The therapeutically effective combination, according to claim 1, wherein the concentration of Irinotecan is in the range of 0.1 µM to 50 µM.

14. The therapeutically effective combination, according to claim 1, wherein the concentration of Paclitaxel is in the range of 0.1 nM to 10 nM.

15. The therapeutically effective combination, according to claim 1, wherein the concentration of Gemcitabine is in the range of 0.01 µM to 300 µM.

16. The therapeutically effective combination, according to claim 1, wherein the concentration of Carboplatin is in the range of 10 µM to 1000 µM.

17. The therapeutically effective combination according to claim 1, wherein the combination is a composition along with one or more pharmaceutically acceptable excipients.